Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Akers Biosciences’ UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer


Posted on: 14 Nov 17

Distributor Accutest Now Selling Through Today’s Group

THOROFARE, N.J, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces that Accutest Solutions (“Accutest”), a distributor of Akers Bio’s BreathScan® Alcohol Detector in the UK, has secured a major new channel partner for sales of the product under Accutest’s own label.

Akers Bio’s BreathScan® Alcohol Detector is a proprietary, single-use, non-mechanical device that measures the user’s blood alcohol concentration in approximately 2 minutes, through a simple breath test.

Accutest has informed the Company that it has begun selling the product in the UK under an agreement with Today’s Wholesale Services Group, a subsidiary of Today’s Group, the largest independent buying group of its kind in the UK, which claims to have buying power exceeding £5.7 billion per annum, including the largest network of independent cash and carry wholesalers and delivered wholesalers in the UK.

Sales are expected to scale up as Accutest rolls out its marketing program from an initial group of Today’s Group wholesaler customers to their full and extensive customer list.  

Accutest is positioning the test as a ‘morning after’ test, which enables users to check if they are safe to drive after consuming alcohol the night before, and can be personalized with their customers’ own branding.

“Akers Bio is delighted that Accutest has cemented an agreement with The Today’s Wholesale Services Group,” said John J. Gormally, CEO of Akers Bio. “Today’s Group is the biggest buying group of its kind in the UK and represents a significant revenue opportunity for Akers Bio. Given Today’s Group’s customers’ buying power, we are confident that sales of this product through Accutest will ramp up as they expand their marketing across an extensive network of UK wholesalers,” added Mr. Gormally.

“1 in 8 deaths on UK roads is caused by people drink driving,” said Richard Canfer-Taylor, CEO of Accutest. “Alcohol stays in the blood for longer than many people realise, in many cases making people unsafe to drive the morning after a night out. With the use of Akers Bio’s unique, single-use, disposable breath test technology, Accutest, through its major buying group partner, Today’s Group, is urging business owners to take responsibility for their customers’ and employees’ well-being and offer a simple, inexpensive tool to check if they’re safe to get behind the wheel,” continued Mr. Canfer-Taylor. “We are seeing a strong pipeline of interest developing in the UK,” he added.


About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

CONTACT: For more information: Akers Biosciences, Inc. John J. Gormally, Chief Executive Officer Raymond F. Akers, Jr. PhD, Executive Chairman and Chief Scientific Director Tel. +1 856 848 8698 Taglich Brothers, Inc. (Investor Relations) Chris Schreiber Tel. +1 917 445 6207 Email: cs@taglichbrothers.com Vigo Communications (Global Public Relations) Ben Simons / Fiona Henson Tel. +44 (0)20 7830 9704 Email: akers@vigocomms.comGlobeNewswire
globenewswire.com

Last updated on: 14/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.